AMRI Hires Chief Information Officer

ALBANY, New York, Feb. 9, 2015 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today that Jimmy Wang, Ph.D., fills the newly created position of Chief Information Officer, effective immediately. He replaces Carl Neumann, Senior Director, Information Technology, who retires this month.

In this role, Dr. Wang will manage and oversee major technology initiatives at AMRI, as well as the day-to-day Information Technology operations. Among his responsibilities will be to implement scalable and agile information technology solutions that align with AMRI's growth objectives and global operations.

"We are pleased to welcome Jimmy to the AMRI team," said William S. Marth, president and chief executive officer, AMRI. "As an award-winning industry professional with a proven track record in delivering complex IT transformations, we look forward to leveraging his strategic direction to create a scalable IT infrastructure that will accommodate growth. We appreciate Carl's many years of dedication and service with AMRI, and wish him the best in his retirement."

Dr. Wang brings 25 years of experience managing and deploying technology innovations to various technology, telecommunications and global pharmaceutical companies. Most recently he served as Senior Vice President and Chief Information Officer at OPKO Health Inc., where he established the company's global IT governance process and transformed IT into a centralized delivery organization. Before OPKO Health, Dr. Wang was Senior Vice President and Chief Information Officer at Vertex Pharmaceuticals Inc., where he played a major role in managing implementation, consolidation, and support of Enterprise Operations Support Systems, as well as led the area of scientific computing to use technology to support the area of Innovation and Research. Before Vertex, Dr. Wang was at Teva Pharmaceuticals-America, where he was Vice President and Chief Information Officer. Dr. Wang received his Ph.D. in Operations Research from Southern Methodist University in 1990.

About AMRI
Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), and Drug Product Manufacturing. Our DDS segment provides comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. API Manufacturing supports the chemical development and cGMP manufacture of complex API, including potent, controlled substances, biologics, peptides, steroids, and cytotoxic compounds. Drug Product Manufacturing supports drug product development through commercial scale production of complex liquid-filled and lyophilized parenteral formulations. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).

Copyright 2015 PR Newswire